CLNN
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Clene Inc. (CLNN) is rated C- (2.0/5) on Deltasharpe Prism, scored against Consumer Defensive sector peers. Its strongest pillar is Growth (B); its weakest is Value (F). The rating has held at C- for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | F (0.0) | B (3.4) | C (2.2) | C- (2.0) | C+ (2.6) | C- (2.0) |
| 2026-11-04 | F (0.0) | B (3.4) | C (2.2) | D (1.2) | C+ (2.6) | C- (1.9) |
| 2026-10-28 | F (0.0) | B (3.3) | C (2.3) | D+ (1.8) | C (2.4) | C- (2.0) |
| 2026-10-21 | F (0.0) | B (3.3) | C (2.3) | D (1.3) | C (2.3) | D+ (1.8) |
| 2026-10-14 | F (0.0) | B (3.3) | C (2.3) | F (0.7) | C (2.4) | D+ (1.7) |